# HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

> **NCT05623189** · PHASE2 · COMPLETED · sponsor: **HighTide Biopharma Pty Ltd** · enrollment: 218 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)
- Type 2 Diabetes

## Interventions

- **DRUG:** HTD1801
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05623189
- **Lead sponsor:** HighTide Biopharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-27
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623189, "HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05623189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*